Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology
Provided By PR Newswire
Last update: May 19, 2023
- Statistically Significant Improvement in Chorea Associated with Huntington's Disease Seen as Early as Week 2
- Chorea Improvement Supported by Statistically Significant Clinical Global Impression of Change (CGI-C) Response Status and Patient Global Impression of Change (PGI-C) Response Status Scores at Week 12
Read more at prnewswire.com116.87
-3.56 (-2.96%)
Find more stocks in the Stock Screener
NBIX Latest News and Analysis
8 days ago - ChartmillTop movers in Monday's after hours sessionLet's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
9 days ago - ChartmillNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is not too expensive for the growth it is showing.Discover NEUROCRINE BIOSCIENCES INC, an undervalued growth gem. NASDAQ:NBIX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
